Efficacy of cadonilimab in combination with nimotuzumab and AG regimen in TMB-H/KRAS wild-type advanced pancreatic cancer: a case report

BackgroundAdvanced pancreatic cancer carries a dismal prognosis. Current chemotherapy provides limited survival benefit while causing substantial toxicity. Despite numerous trials, combining gemcitabine with other cytotoxic or targeted agents has not significantly improved outcomes, highlighting the...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Zhiwei Tang, Jiegang Hu, ZhongShi He, Dongdong Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-09-01
Subjects:	advanced pancreatic cancer tumor mutational burden (TMB-H) KRAS wild-type cadonilimab nimotuzumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1652827/full